A systematic review and meta-analysis of thiazide-induced hyponatraemia: time to reconsider electrolyte monitoring regimens after thiazide initiation?

Running Title: TIH systematic review

Authors: Jennifer Barber BMedSci¹*, Tricia M. McKeever PhD²*, Sarah E. McDowell PhD³, Jennifer A. Clayton DM MB BS⁴, Robin E.Ferner MD MB BS³, Richard D. Gordon PhD MBBS⁵, Michael Stowasser PhD MBBS⁵, Kevin M. O’Shaughnessy DPhil BM BCh⁶, Ian P.Hall DM MB BCh¹ and Mark Glover PhD MB BChir¹**

Positions and addresses:

¹ Medical Student (JB), Professor of Therapeutics (IPH) and MRC Clinician Scientist (MG), Division of Therapeutics and Molecular Medicine, University of Nottingham, Nottingham, NG7 2UH, United Kingdom, ² Associate Professor and Reader, Division of Epidemiology and Public Health, University of Nottingham, Nottingham, NG5 1PB, United Kingdom, ³ Professor of Clinical Pharmacology (REF) and Post-doctoral research fellow (SMD), West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, B18 7QH, United Kingdom, ⁴ Consultant Physician, Department of Diabetes and Endocrinology, Nottingham University Hospitals NHS Trust, Nottingham, NG7 2UH, United Kingdom, ⁵ Professor of Medicine (RDG and MS), Endocrine Hypertension Research Centre, University of Queensland School of Medicine, Brisbane, Australia, ⁶ Senior Lecturer, Clinical Pharmacology Unit, Department of Medicine, University of Cambridge, Cambridge, CB2 2QQ, United Kingdom.

*joint first authors

**Correspondence to: Dr M. Glover, Division of Therapeutics and Molecular Medicine, Queen’s Medical Centre, Nottingham, NG7 2UH, UK.

E-mail: mark.glover@nottingham.ac.uk
Structured summary: 244 words

Body of manuscript: 3076 words

Number of Figures: 1

Number of Tables: 4

Number of online supplements: 1
Structured summary

Aims: Hyponatraemia is one of the major adverse effects of thiazide diuretics and the leading cause of drug-induced hyponatraemia requiring hospital admission. We sought to review and analyse all published cases of this important condition.

Methods: Ovid Medline, Embase, Web of Science and PubMed electronic databases were searched to identify all relevant articles published before October 2013. A proportions meta-analysis was undertaken.

Results: 102 articles were identified of which 49 were single patient case reports. Meta-analysis showed that mean age was 75 (95% CI 73–77) years, 79% were women (95% CI 74–82) and mean body mass index was 25 (95% CI 20–30) kg/m². Presentation with thiazide-induced hyponatraemia occurred a mean of 19 (95% CI 8–30) days after starting treatment, with mean trough serum sodium concentration of 116 (95% CI 113 to 120) mM and serum potassium of 3.3 (95% CI 3.0 to 3.5) mM. Mean urinary sodium concentration was 64 mM (95% CI 47 to 81); the most frequently reported thiazides were hydrochlorothiazide, indapamide and bendroflumethiazide.

Conclusions: Patients with thiazide-induced hyponatraemia were characterised by advanced age, female gender, inappropriate saliuresis and mild hypokalaemia. Low BMI was not found to be a significant risk factor, despite previous suggestions. The time from thiazide initiation to presentation with hyponatraemia suggests that the recommended practice of performing a single investigation of serum biochemistry 7–14 days after thiazide initiation may be insufficient or suboptimal. Further larger and more systematic studies of thiazide-induced hyponatraemia are required.
What is known about this subject

• Thiazide/thiazide-like diuretics are amongst the top 5 most prescribed medicines in the UK and one of the most widely prescribed and effective anti-hypertensive classes of medication worldwide.

• Most physicians are familiar with prescribing thiazides and of their limiting side effects, of which hyponatraemia is amongst the most commonly encountered and medically serious.

• Thiazide-induced hyponatraemia is the leading cause of drug-induced hyponatremia requiring hospitalisation in the UK.

What this study adds

• This systematic review and meta-analysis is the first time (to our knowledge) that anyone has attempted to analyse the entire published literature (1962-2013) on this common and serious adverse drug effect.

• This work challenges the perception that underweight patients are those who typically suffer from this side effect and, if people are sticking to the rules with serum electrolyte monitoring, calls into question whether the standard UK practise of a blood test 1-2 weeks after starting thiazides is optimal since the mean time to presentation with hyponatraemia occurred outside (after) this monitoring period.
**Introduction**

Thiazide and thiazide-like diuretics, although they differ in chemical structure, all inhibit the thiazide-sensitive sodium–chloride co-transporter, NCC, in the distal convoluted tubule of the kidney [1]. Since the demonstration of their anti-hypertensive effect in 1958 [2] they have been widely used in the management of hypertension, and continue to be so, notwithstanding their recent and controversial demotion to step 3 in UK hypertension guidance [3,4]. Their benefits on all-cause mortality are equal to those of angiotensin-converting enzyme (ACE) inhibitors and calcium channel antagonists [5,6].

However thiazide diuretics often cause adverse effects, of which thiazide-induced hyponatraemia is amongst the most clinically important [7]. Thiazide-induced hyponatraemia may also represent a scientifically important paradigm of the dysregulation of sodium (and water) transport within the distal nephron [8].

Thiazide diuretics are the most common cause of drug-induced hyponatraemia in secondary care [9]. Severe thiazide-induced hyponatraemia causes debilitating symptoms such as confusion, falls and seizures, and can sometimes be fatal [7]. Thiazide-induced hyponatraemia necessitating hospital admission is common enough to suggest that current monitoring regimens are suboptimal [9]. Importantly, the mechanism of thiazide-induced hyponatraemia is also poorly understood; mean serum sodium concentration in the total treated population is virtually unchanged by thiazide therapy [10], implying that thiazide-induced hyponatraemia occurs in a susceptible subgroup. However this subgroup cannot be prospectively identified at present and so thiazide-induced hyponatraemia is largely unpredictable at the point of thiazide initiation. We therefore set out to undertake a systematic review and meta-analysis of all thiazide-induced hyponatraemia reports published to date in order to summarise and reflect on current understanding of this condition.
Methods

Search strategy
Medline, Embase, Web of Science and PubMed databases were searched on 1st October 2013 without limitation on language. The Ovid interface was used to search Medline and Embase using the terms “thiazide AND hyponatraemia”, “thiazide-induced hyponatraemia” and “thiazide-associated hyponatraemia”. Web of Science and PubMed were searched using the terms “(thiazide AND (hyponatraemia OR hyponatraemia))”, “(thiazide-induced AND (hyponatraemia OR hyponatraemia))”, “(thiazide-associated AND (hyponatraemia OR hyponatraemia))”. Database searches were also undertaken with the term ‘thiazide’ replaced alternatively by either ‘indapamide’ or ‘chlortalidone’. Articles that cited or were cited by the included studies were also screened to identify any further relevant studies. Duplicated results and studies containing no primary data or non-human data only were removed. The conventional definition for hyponatraemia of serum sodium concentration ≤135mM was used [11,12].

Data extraction
Two authors (JB and MG) independently reviewed the titles, abstracts and full text of identified papers. References of all full text papers were searched to identify any additional pertinent papers. Disagreements were resolved by discussion. Data extraction was performed using a structured template to collect information on study design (including location of study and year of publication) and thiazide-induced hyponatraemia phenotype including age, sex, presenting symptoms, drug history including concomitant drug use and laboratory findings. Methodological quality was independently rated by two authors (JB and MG) using a modified version scale developed for observational studies 13. The range of possible scores was 0-12.

Data analysis
Study parameters which were reported in more than 1% of patients are presented. We excluded from the analysis any measurement given qualitatively as “normal” without any indication of the
value itself or the reference range. For publications in which more than one patient was reported
a proportions meta-analysis was conducted to look at the weighted frequency of clinical
phenotype, drug history and laboratory findings for the combined number of papers contributing
to each separate analysis. A random effects model was used to determine 95% confidence
intervals, using the DerSimonian and Laird method to calculate weights [14]. Study
heterogeneity was assessed using $I^2$ scores. Causes of high levels of heterogeneity were explored
by dividing the following variables at the median level: quality score, year of publication, and
age of study population. Evidence for the possibility of publication bias was assessed by funnel
plots. Single case reports were simply summarised.

The presentation of the meta-analyses adhered to the Meta-analysis of Observational
Studies in Epidemiology (MOOSE) consensus statement [15]. All proportional analyses were
performed using the Stats Direct® statistical software package version 2.7.9 and Stata® version
12 for the meta-analyses of mean values.

**Results**

Database searches resulted in 1359 citations. After exclusion of duplicates and articles where
data was non-human or irrelevant to thiazide-induced hyponatraemia in adults, 102 articles
remained (median date of publication was 1998, range 1962-2013) and were analysed (Figure 1).
Of the 102 articles analysed, 49 were single case reports [16-64] (Supplementary Table 1) and
the remaining 52 articles ranged from 2 to 1802 patients [65-117] (Supplementary Table 2). 4
papers were also removed because the same study population was already represented in the 102
articles included in the review [118-121].

The mean value for quality score was 4.0 (range 1–8) for studies included in the meta-
analysis and 3.2 for single case reports (range 1–6). The main reasons for low quality scores
were a lack of clearly stated inclusion and exclusion criteria, absence of documented patient
consent and/or ethical approval, a lack of inclusion of patient perception, a lack of clarity
regarding the name, dose and duration of thiazide therapy and whether thiazide-induced hyponatraemia patients represented a consecutive series treated consistently by the same physician(s) or at a single institution.

**FIGURE 1 HERE**

**Meta-analysis Findings**

**Clinical Characteristics**

Patients with thiazide-induced hyponatraemia had a mean age of 75 years (pooled estimate, 95% CI 73 to 77 years, based on 36 studies and 2840 patients, Figure S1), 79% were women (95% CI 74–82%, $I^2 = 65\%$, based on 43 studies and 3269 patients, Figure S2) and mean body mass index was 25 kg/m$^2$ (pooled estimate, 95% CI 20–30 kg/m$^2$, $I^2 = 100\%$, based on 2 studies and 2025 patients, Figure S3). Thiazide-induced hyponatraemia was first detected a mean of 19 days (pooled estimate, 95% CI 8–30 days, $I^2 = 97\%$, based on 19 studies and 446 patients, Figure S4) after starting thiazide treatment (Table 1). Sensitivity analysis by removal of studies with delay to thiazide-induced hyponatremia >100 days also showed the time to detection was greater than the standard 7-14 day serum electrolyte monitoring period (17 days, 95% CI 6 to 28 days, based on 14 studies with 415 patients). The levels of heterogeneity were explored by quality score, year of publication and age of patients; however none of these factors could explain the high levels of heterogeneity (Table S3).

Clinical characteristics of patients with thiazide-induced hyponatraemia are presented in Table 2 (Meta-analyses graphs Figures S5 to S14). The most frequently reported symptoms at presentation were: falls (48%, 95% CI 20 to 77%, $I^2 = 84\%$, based on 5 studies and 252 patients); fatigue (46%, 95% CI 21 to 72%, $I^2 = 92\%$, based on 8 studies and 333 patients); weakness (45%, 95% CI 32 to 58%, $I^2 = 49\%$, based on 14 studies and 247 patients); confusion (44%, 95% CI 33 to 56%, $I^2 = 85\%$, based on 22 studies and 710 patients); nausea (36%, 95% CI 24 to 48%, $I^2 = 76\%$, based on 14 studies and 405 patients); and vomiting (35%, 95% CI 25 to 45%, $I^2 = 68\%$,
based on 13 studies and 549 patients). Also reported were other neurological symptoms, dizziness, unconsciousness and seizures (Table 2). Analyses of clinical characteristics revealed substantial heterogeneity between studies which were not explained by quality score, year of publication or age of patient (Table S4).

Co-morbidities

The most commonly reported comorbidities included cardiovascular disease (49%, 95% CI 33 to 65%, \(I^2 = 72\%\), based on 12 studies and 284 patients, Figures S15) and diabetes mellitus (27%, 95% CI 14 to 42%, \(I^2 = 99\%\), based on 9 studies and 3029 patients, Figure S16). Analyses of comorbidities revealed substantial heterogeneity between studies which was not explained by quality score, year of publication or age of patient (Table S3). A single study of 1802 patients reported the prevalence of gastro-oesophageal reflux disease (24%), hyperlipidemia (47%) and urinary tract infection (24%) [104].

Medication history

Thiazide-induced hyponatraemia was reported in association with a wide range of thiazide/thiazide-like drugs (Table 3, meta-analyses graphs in Figures S17 to S22). By far the most frequently implicated was hydrochlorothiazide either alone (68%, 95% CI 52 to 82%, \(I^2 = 97\%\), based on 19 studies and 2583 patients) or in combination with amiloride (as Moduretic\textsuperscript{®}, 73%, 95% CI 57 to 87%, \(I^2 = 92\%\), based on 19 studies and 633 patients) or triamterene (as Dyazide\textsuperscript{®}, 18%, 95% CI 8 to 32%, \(I^2 = 36\%\), based on 3 studies and 59 patients). Other thiazide/thiazide-like drugs implicated were indapamide, bendroflumethiazide (bendrofluazide), and chlortalidone. Analyses of which individual thiazide/thiazide-like drugs were associated with hyponatraemia revealed high levels of heterogeneity between studies and this was not explained by quality score, year of publication or age of patient (Table S4).
Details of concurrent non-thiazide medication in patients with thiazide-induced hyponatraemia are presented in Table 3 (meta-analyses graphs Figures S23 to S28). Commonly reported non-thiazide co-prescriptions were angiotensin II receptor antagonists (59%, 95% CI 0 to 96%, $I^2 = 99\%$, based on 3 studies and 1844 patients), Angiotensin Converting Enzyme (ACE) inhibitors (51%, 95% CI 27 to 75%, $I^2 = 96\%$, based on 5 studies and 2000 patients), non-thiazide diuretics (e.g. loop- and potassium sparing-diuretics) (58%, 95% CI 19 to 91%, $I^2 = 86\%$, based on 5 studies and 1815 patients), Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) (33%, 95% CI 18 to 49%, $I^2 = 89\%$, based on 6 studies and 2036 patients), and anti-depressants (32%, 95% CI 19 to 47%, $I^2 = 68\%$, based on 6 studies and 1882 patients). While Selective Serotonin Reuptake Inhibitors (SSRIs) are associated with hyponatraemia, there was insufficient data to determine what proportion of the anti-depressant medication reported were SSRIs.

Analyses of polypharmacy demonstrated high levels of heterogeneity between studies, which was not explained by quality score, year of publication or age of patient (Table S5).

**Laboratory Characteristics**

As shown in Table 4 (Figures S29 to S34), thiazide-induced hyponatraemia patients had severe hyponatraemia, with a mean trough serum sodium concentration of 116 mM (95% CI 113 to 120 mM, $I^2=99\%$, based on 37 studies and 1042 patients), mild hypokalaemia, with serum potassium 3.3 mM (95% CI 3.0 to 3.5 mM, $I^2=97\%$, based on 28 studies and 902 patients), and normal renal function, serum creatinine 76.8 µmol/L (95% CI 64.1 to 89.4 µmol/L, $I^2=99\%$, based on 17 studies and 504 patients). Corresponding urinary electrolyte data indicates inappropriate saliuresis, with urinary sodium concentration 64 mM (95% CI 47 to 81 mM, $I^2=94\%$, based on 13 studies and 98 patients). Mean serum and urine osmolalities were 240 mOsm/kg (95% CI 236 to 245 mOsm/kg, $I^2=80\%$, based on 11 studies and 229 patients) and 402 mOsm/kg (95% CI 370 to 432 mOsm/kg, $I^2=81\%$, based on 14 studies and 322 patients) respectively. In most analyses
of laboratory characteristics there were high levels of heterogeneity between studies, which were not explained by quality score, year of publication or age of patient (Table S6).

Discussion

We present, to our knowledge, the first systematic review and meta-analysis of the observational literature regarding the clinical and laboratory characteristics of thiazide-induced hyponatraemia. Patients with thiazide-induced hyponatraemia were characterised by advanced age, female gender, inappropriate saliuresis and mild hypokalaemia. In addition, patients had normal BMI, in contrast to suggestions that such patients tend to be underweight [7].

The most notable finding is of the delay from thiazide initiation to diagnosis of thiazide-induced hyponatraemia which averaged 19 days (95% CI 8 to 30 days, Figure S4). Current best practice is to measure serum biochemistry 1–2 weeks after thiazide initiation [122]. Our data suggest that either best practice is not followed [123], or that testing at 1–2 weeks fails to detect some patients who go on to develop thiazide-induced hyponatraemia [9] in which case changes in monitoring schedules might improve current practice. Without data reporting either the frequency of routine biochemical monitoring or the levels of serum sodium from such monitoring it is not possible to confidently recommend what the optimal timing of a single electrolyte check should be or whether there would be merit in performing a second electrolyte measurement after the initial fortnight following thiazide initiation, e.g. at 3–4 weeks. Since in a few cases, severe hyponatraemia developed many months or even years after thiazide initiation, it would be prudent to measure serum electrolyte concentrations whenever patients treated with thiazides develop symptoms suggestive of hyponatraemia, regardless of the duration of thiazide therapy.

Mild hypokalaemia accompanying thiazide-induced hyponatraemia may occur simply as a consequence of excessive saliuresis and consequent electrogenic exchange of potassium for sodium in the collecting duct. Additional mechanisms may also contribute; for example (1)
aldosterone activation of the distal nephron, as is to be expected and not uncommonly seen with thiazide-induced hypokalaemia and hyperaldosteronism [124], or (2) With No lysine protein Kinase (WNK) regulation of the renal outer-medullary potassium channel (ROMK) in the collecting duct and the thiazide-sensitive sodium chloride cotransporter (NCC) in the distal convoluted tubule as has been proposed for the hyperkalemia seen in Gordon syndrome [125], a Mendelian disorder of thiazide-responsive hypertension and metabolic acidosis.

Hyperlipidemia was the most common comorbidity. Whilst severe hyperlipidemia is a well-recognised cause of pseudo-hyponatraemia in older studies that relied on methods such as flame photometry to measure serum sodium concentration, most dyslipidemia is very unlikely to affect modern assay methods. The second most common comorbidity was diabetes mellitus. Plasma glucose concentration was reported infrequently and it is possible that hyperglycemia could have contributed to hyponatraemia in some cases. Since for the vast majority of patients reported the indication for thiazide prescription was hypertension and presentation was with symptomatic hyponatraemia it is not possible to make meaningful conclusions either regarding thiazide-induced hyponatraemia when thiazide prescriptions were for indications other than hypertension or the differences between symptomatic versus non-symptomatic patients.

Several of the medicines most commonly co-prescribed with thiazides among studies included in this meta-analysis, such as ACE inhibitors, AT₁ receptor antagonists, NSAIDS and some anti-depressants, are associated with hyponatraemia through well-described mechanisms. This raises the possibility that some cases of apparent thiazide-induced hyponatraemia could result from pharmacodynamic interactions of these drugs with thiazides. It was also notable that hypokalaemia was seen despite the frequency of concurrent therapy with ACE inhibitors, AT₁ receptor antagonists and potassium supplements.

The finding of a normal serum creatinine concentration is unexpected in such an elderly cohort at higher than average vascular risk, many of whom also took ACE inhibitors, ARBs
and/or NSAIDs. BMI was normal, so low muscle mass is unlikely to predominantly account for this raising the possibility of a dilutional component to the observed serum creatinine concentrations. Thus in addition to inappropriate saliuresis and inappropriately high urinary osmolarity, inappropriately low serum creatinine concentration is consistent with volume expansion and the overall phenotype could therefore be alternatively described as having much in common with thiazide-induced Syndrome of Inappropriate Anti-Diuretic Hormone secretion (SIADH) [126].

There are significant limitations to this systematic review. Included studies were very heterogenous with respect to the detail of their description, specific parameters recorded and laboratory methods used and this did not appear to be explained by either individual study quality, median date of publication, or whether the study pertained to a particular ‘specialist group’. One possible explanation for the high level of heterogeneity found in the analyses may be the local prescribing habits of the areas in which these often small studies were undertaken given that case series usually focused on small numbers from a single institution over a relatively short project interval. Case reports were excluded from our meta-analysis but we accept that a case report may describe unusual but important presenting clinical and laboratory characteristics of patients with thiazide-induced hyponatraemia. For this reason we have presented a summary of the case report data alongside that for the meta-analysis in Tables 1-4. It is also possible that some publications were not identified by our search of the four principal databases used, however the extensive searches and the searching of references list limits the possibility of many missing articles. Publication bias is still a possibility; however none of the funnel plots from the meta-analyses indicated that this was a problem. The vast majority of reports detailed patients who had been admitted to hospitals with symptomatic hyponatraemia and it is therefore likely that asymptomatic and non-hospitalised patients with thiazide-induced hyponatraemia are underrepresented.
There are also specific issues with respect to the phenotypic parameters measured by observational studies; advanced age is confounded by the prescribing of thiazides to older patients and the over-representation of females may be confounded by the shorter life expectancy of males. Although oestrogens do affect sodium transport via the thiazide-sensitive NCC [127], the age of the cohort reported would put the vast majority well beyond the menopause. Alternatively perhaps the sex distribution is pathophysiologically significant; in the age category 70–74 years for the UK in the median year of publication (1998), females constituted only 55% of the population [128] and yet 73% of thiazide-induced hyponatraemia patients in our meta-analysis were female.

It is not possible to draw meaningful conclusions regarding the prevalence of thiazide-induced hyponatraemia with respect to individual thiazide drugs from the available data, apart from observing that thiazide-induced hyponatraemia is reported with many thiazides including indapamide and chlortalidone, the two currently recommended thiazide-like diuretics for hypertension in the UK [4].

The detailed study of the phenotype and pathophysiology of patients with thiazide-induced hyponatraemia has the potential not only to improve clinical care of patients prescribed thiazides but also potentially to uncover novel pathophysiological insights into salt and water handling in the kidney which are clearly disturbed in these individuals. In the absence of a prospective trial exposing thousands of patients to thiazides with extensive follow up (which is unlikely due to prohibitive expense and limited interest from pharmaceutical companies given the very old non-patented nature of thiazides), larger scale prospective observational studies with detailed phenotyping of thiazide-induced hyponatraemia patients is required. Such a study is already taking place across several acute hospitals throughout the UK (NIHR CRN portfolio identity 10795).
In conclusion this study found that patients with thiazide-induced hyponatraemia were
characterised by advanced age, female gender, inappropriate saliuresis and mild hypokalaemia.
Such patients had a normal BMI and were diagnosed later than the usual serum electrolyte
monitoring interval of 7-14 days after thiazide commencement. Until further studies determine
the optimal timing and frequency of electrolyte monitoring regimens it would seem prudent to be
mindful of the development of hyponatraemia outside of the first fortnight of thiazide therapy.

Acknowledgements and competing interests declarations

This work was supported by a Clinician Scientist award from the Medical Research
council (MG) and an Academy of Medical Sciences starter grant for Clinical Lecturers (MG).
All authors have completed the ICMJE uniform disclosure form at
http://www.icmje.org/coi_disclosure.pdf and declare: Dr. Glover reports a Clinician Scientist
grant from Medical Research Council and a starter grant for clinical lecturers from the Academy
of Medical Sciences, for the submitted work. Dr Glover and Dr Clayton report a grant from
Otsuka, outside the submitted work in the previous three years. Professor Ferner reports
providing expert medico-legal evidence on adverse drug reactions. There are no other
relationships or activities that could appear to have influenced the submitted work. None of the
funders had any role in study design; in the collection, analysis, and interpretation of data; in the
writing of the report; or in the decision to submit the article for publication.

References

1. Glover M, Mercier Zuber A, O'Shaughnessy KM. Hypertension, Dietary Salt Intake, and the
   Role of the Thiazide-Sensitive Sodium Chloride Transporter NCCT. Cardiovasc Ther
   2011; 29: 68-76.


6. The ALLHAT officers and coordinators for the ALLHAT collaborative research group. Major outcomes in high-risk hypertensive patients randomized to angiotensin converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA 2002; 288: 2981-2997.


60. Strykers PH, Stern RS, Morse BM. Hyponatraemia induced by a combination of amiloride and hydrochlorothiazide. JAMA 1984; 252: 389.


**Figures**

**Figure 1:** Flow diagram of steps in systematic review in PRISMA format.

**Tables**

**Table 1:** Analysis of pooled data of the age, gender, BMI and duration of thiazide therapy of patients with thiazide-induced hyponatraemia.

<table>
<thead>
<tr>
<th>Body Mass Index (BMI), TIH (Thiazide Induced Hyponatraemia), Confidence Interval (CI), Pop (Contributing population to the meta-analyses, number of studies/total number of patients with the studies), Standard deviation (SD) and N (number of patients in single case reports).</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>* Data expressed as proportion</td>
<td></td>
</tr>
</tbody>
</table>

**Table 2:** Meta-analysis of the symptoms reported at presentation in patients with thiazide-induced hyponatraemia.

Prevalence estimates from meta-analysis and confidence intervals are all expressed as proportions. Prop (proportion), Pop (Contributing population to the meta-analyses, number of
studies/total number of patients with the studies), Confidence Interval (CI), N (number of single case reports reporting the variable listed).

Table 3: Meta-analysis of the drug history in patients with thiazide-induced hyponatraemia.
Prevalence estimates from meta-analysis and confidence intervals are all expressed as proportions of those studies that reported each given variable at least once. HydroChloroThiaZide (HCTZ), AngioTensin Converting enzyme (ACE) inhibitor, Non-Steroidal AntiInflammatory Drug (NSAID), Angiotensin Receptor Blocker (ARB), Prop (proportion), Pop (Contributing population to the meta-analyses, number of studies/total number of patients with the studies), Confidence Interval (CI), N (number of single case reports reporting the variable listed).

Table 4: Meta-analysis of laboratory characteristics in patients with thiazide-induced hyponatraemia.
Prevalence estimates from meta-analysis and confidence intervals are all expressed as proportions. Confidence Interval (CI), N (number of single case reports reporting the variable listed), Standard deviation (SD).